Altimmune to Present at Upcoming Investor and Scientific Conferences

GAITHERSBURG, Md., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc., (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following conferences during the months of February:

2020 BIO CEO & Investor Conference
Date:    Monday, February 10
Time:  10:45am ET
Title:  Altimmune, Inc. Overview
Speaker:  Vipin K. Garg Ph. D., President and Chief Executive Officer
Location:  New York Marriott Marquis, New York, NY
The 3rd Global NASH Conference
Date:    Tuesday, February 11
Time:  11:55 am GMT / 6:55 am ET
Title:    Dual GLP-1 Agonists in the Treatment of Metabolic & Liver Dysfunction in NASH
Speaker:  M. Scott Harris M.D., Chief Medical Officer
Location:  The London Heathrow Marriott Hotel, London, UK

About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver diseases and immune modulating therapies. The Company’s diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoShield™ and NasoVAX™). For more information on Altimmune, please visit

Will Brown   Ashley R. Robinson
Chief Financial Officer   Managing Director LifeSci Advisors
Phone: 240-654-1450   Phone: 617-535-7742
Email:   Email:

Primary Logo

Back to news